The Diary of a CEODr. Alex Tatem: Why peptide regulation built a gray market
How short amino-acid sequences unlock targeted cell receptors. Why 2023 rules pushed peptide access into a gray market shaping GLP-1 obesity care.
CHAPTERS
- 0:00 – 2:59
Controversial peptide claims: belly-fat loss, liver health, and a coming FDA decision
The episode opens with bold claims about next-generation peptides—especially powerful fat-loss compounds with surprising liver-health benefits. Dr. Tatem previews major FDA movement that could re-legalize several peptides and frames why this matters to patients and to pharmaceutical business models.
- •Peptide teased as disproportionately effective for belly fat and liver health
- •FDA expected to consider legalizing seven peptides in July
- •Discussion of why peptide access threatens pharma economics
- •Set-up of the table of different peptides and their promised effects
- •Early warning: benefits come with trade-offs
- 2:59 – 6:54
What peptides are (and how they differ from typical drugs): amino-acid “keys” for specific “locks”
Steven asks the fundamental question: what is a peptide? Dr. Tatem explains peptides as amino-acid fragments engineered to target receptors more precisely than many small-molecule drugs, using “key-and-lock” and “toolbox” analogies.
- •Peptides are built from amino acids (protein building blocks)
- •They can be more targeted than small-molecule drugs
- •“Key/lock” framing: peptides interact with specific receptors/pathways
- •Insulin is highlighted as the first major medical peptide (1921)
- •Why specificity can reduce unintended side effects
- 6:54 – 9:24
How peptides work in practice: the BPC-157 injury-repair example and safety questions
Dr. Tatem uses BPC-157 to illustrate how a peptide can influence healing—particularly via blood-vessel growth (angiogenesis) and tissue repair. He contrasts exciting animal data with the need for better human data and explains key safety concepts like LD50.
- •BPC-157 described as a synthetic version of a gut-derived peptide
- •Mechanism focus: angiogenesis and repair at injury sites
- •Animal model example: surgically cut Achilles tendon healing in rats
- •Safety discussion: LD50/LD1 concepts and tolerability signals
- •Caution: promising results aren’t automatically 1:1 in humans
- 9:24 – 11:29
Why peptides suddenly exploded: patent incentives, compounding regulation, and the 2023 “overnight” ban
The conversation shifts to the systems-level story behind peptide availability. Dr. Tatem links the peptide boom to a Supreme Court ruling limiting patents on naturally occurring biology and to FDA oversight changes after a compounding-pharmacy contamination scandal—culminating in a sudden FDA reclassification that banned many popular peptides.
- •2013 Myriad Genetics case reduced patentability of naturally occurring biology
- •Pharma incentives weakened for compounds that can’t be monetized
- •Compounding pharmacy contamination event led to tighter federal oversight
- •FDA categories for compoundable ingredients (1/2/3) explained
- •In 2023, 19 peptides moved to Category 2 and were effectively banned
- 11:29 – 20:53
Compounding pharmacies 101: what they are and why they became central to peptide access
Steven asks for a clear definition of compounding pharmacies. Dr. Tatem explains their historical roots, modern industrial scale, and the role they play in personalized dosing when standardized, mass-produced medication doesn’t fit patient needs.
- •Compounding as custom medication-making vs factory standardization
- •Why “one dose for all adults” can be imperfect
- •Modern compounders as large, sophisticated operations
- •Economic reality: drug development costs vs limited IP protection
- •How compounding became the bridge for “stuck-in-limbo” compounds
- 20:53 – 28:03
Banned but still used: the “forbidden fruit” effect, gray markets, and the new FDA July update
After the ban, interest surged rather than faded. Dr. Tatem describes how social media accelerated demand, how gray-market sellers exploited “research use only” labeling, and what the FDA’s April announcement could change if seven peptides move back to the compoundable list.
- •Peptide popularity rose due to TikTok/short-form virality and curiosity
- •“Research use only” products as a workaround outside normal controls
- •Quality-control risk analogy: ‘gas station sushi’
- •FDA press release: July review to move seven peptides back to Category 1
- •List highlights: BPC-157, TB-500, KPV, MOTS-c, Semax, Epithalon, DSIP
- 28:03 – 34:13
How peptides are taken safely: why most are injected, dosing pitfalls, and GLP-1 compounding controversy
Dr. Tatem explains why oral peptides typically get digested into amino acids, making injections the standard route. The discussion then turns to GLP-1s (e.g., tirzepatide) and why compounded versions—often enabling microdosing flexibility—have become a flashpoint with regulators and drug makers.
- •Why oral peptides usually break down like dietary protein
- •Common administration routes: subcutaneous vs intramuscular
- •Auto-injector pens vs vials requiring dose calculation skills
- •Compounded tirzepatide allows flexible microdosing schedules
- •Claimed crackdown pressure: FDA enforcement vs pharma patent/economic concerns
- 34:13 – 39:02
When peptides make sense (and when they don’t): realistic expectations for fat loss, muscle gain, and insulin resistance
Steven presses on what Dr. Tatem personally uses and why he avoids gray-market compounds. They clarify which outcomes are realistic—GLP-1s for metabolic health, limited “muscle in a vial” potential—and how some growth-hormone pathways can worsen glucose control.
- •Dr. Tatem uses low-dose tirzepatide for health/longevity goals
- •He avoids non-legal peptides to model safe behavior for patients
- •Muscle gain claims are overstated; training stimulus still required
- •IGF-1 variants discussed but not positioned as magic muscle builders
- •GLP-1s improve insulin sensitivity via slower gastric emptying
- 39:02 – 50:52
Topicals, cognition, and sleep: what might work (GHK-Cu creams, intranasal Semax, circadian peptides)
The conversation moves from injections to other delivery methods and targeted goals. Dr. Tatem highlights GHK-Cu as a topical option for skin quality, describes intranasal Semax for cognition (pending legality), and outlines peptides aimed at circadian rhythm and sleep depth.
- •GHK-Cu copper tripeptide for collagen/elastin and skin regeneration
- •Topical vs injectable regulatory differences
- •Intranasal Semax: history of use in TBI/stroke recovery studies
- •Circadian/sleep-related candidates: DSIP/Epithalon and calming agents
- •Emphasis: careful language—education, legality, and data still evolving
- 50:52 – 51:37
The hidden trade-offs: contamination risk, dependency, and what happens when you stop GLP-1s
Steven frames the “no free lunch” principle and pushes on downsides. Dr. Tatem emphasizes that the biggest near-term trade-off is quality assurance in unregulated markets and explains why benefits can fade when medication stops without lifestyle changes.
- •Core trade-off: you may not be getting what you think you bought
- •Endotoxins/contamination and mislabeling risks in gray-market peptides
- •Some outcomes reverse if the intervention is removed (without lifestyle change)
- •Stopping GLP-1s often leads to weight regain; maintenance strategies exist
- •Peptides as tools—not substitutes for training, nutrition, and habits
- 51:37 – 56:16
Comparing real-world peptides: visceral-fat strippers, tanning/erection effects, and next-gen GLP-1s (retatrutide)
Dr. Tatem walks through several headline-grabbing compounds, explaining intended effects and potential risks. The discussion escalates to retatrutide—a triple-agonist drug in development—already being used off-label via research markets, raising questions about safety, access, and commercialization.
- •Tesamorelin: growth-hormone pathway peptide known for reducing visceral fat
- •Melanotan II: tanning effects plus strong erectile response; safety concerns raised
- •Retatrutide: GLP-1/GIP/glucagon triple agonist—major weight and liver-health effects
- •Observation: public adoption can outpace full commercialization
- •Pharma ownership/patents vs patient demand and market behavior
- 56:16 – 1:08:14
Growth hormone and ‘anti-aging’ promises: secretagogues, side effects, and telomere skepticism
The episode digs into growth-hormone biology and the peptides used to stimulate it (like CJC-1295 and ipamorelin). Dr. Tatem also addresses epithalon’s anti-aging reputation via telomerase/telomere theory, while stressing skepticism and safety boundaries.
- •Secretagogues discussed as a ‘more natural’ GH-release approach
- •Potential GH benefits: recovery, body composition, sleep, skin/hair/nails
- •Risks of excess GH: insulin resistance, acromegaly-like changes, edema/numbness
- •Cancer-growth concern framed as theoretical risk amplification, not proven causation
- •Epithalon: telomerase/telomere mechanism explained; fountain-of-youth claims questioned
- 1:08:14 – 1:12:14
A bigger health crisis: male fertility decline, metabolic disease as a root cause, and why GLP-1s might change the trajectory
Steven brings out three vials representing sperm-count decline over decades, prompting a discussion about the fertility trajectory in men. Dr. Tatem points to environmental toxins and microplastics but stresses obesity/insulin resistance as the largest modifiable driver—and suggests metabolic peptides could indirectly improve fertility outcomes at population scale.
- •Evidence-based concern: declining sperm count, motility, and concentration over time
- •Suspected contributors: microplastics, environmental toxins, endocrine disruption
- •Major modifiable factor: obesity and insulin resistance impacting hormones and fertility
- •GLP-1-enabled weight loss tied to improved fertility markers in clinical anecdotes
- •Metabolic dysfunction linked broadly to cardiovascular disease, ED, cancer risk
- 1:12:14 – 1:19:17
Why Dr. Tatem cares: medical burnout, personal fertility struggle, and a patient-first mission
The tone turns personal as Dr. Tatem describes the physical and psychological cost of surgical training and a formative complication case that shook him. He connects that experience to his commitment to self-care, to treating men’s health issues, and to advocating for broader access to safe, effective tools.
- •80–100 hour weeks in training and the long recovery afterward
- •A high-stakes surgery complication story and its emotional impact
- •Diagnosed low testosterone after prolonged stress and deprivation
- •Personal IVF experience informs empathy for fertility patients
- •Mission: expand safe access while keeping care equitable beyond elites
- 1:19:17 – 1:21:57
Enhanced Games and the future of performance enhancement: regulated doping vs reality
Steven asks about the Enhanced Games, a proposed competition allowing performance-enhancing drugs under medical oversight. Dr. Tatem outlines the rationale, the economics for athletes, and the controversy around what will actually be tested or permitted.
- •Claim: significant portion of elite athletes have used banned substances
- •Premise: allow enhancement with medical monitoring and transparency
- •Financial incentives: large prizes for wins and world records
- •Stated constraint: ‘FDA-approved only’ vs practical enforcement ambiguity
- •Ethics and safety debate: oversight vs normalization of enhancement
- 1:21:57 – 1:29:48
Erectile dysfunction solutions: why pills fail, penile implants, and how the device works
The closing segment dives into Dr. Tatem’s surgical specialty: end-stage erectile dysfunction. He explains ED as a vascular/metabolic issue, why Viagra/Cialis can stop working, and how internal penile implants restore function without affecting sensation.
- •ED framed as an end-stage consequence of vascular disease/diabetes
- •Oral meds fail in a significant share of men; injections are a less appealing step
- •Penile implant explained as internal cylinders + hidden pump + reservoir
- •Mechanics: pump transfers saline to create rigidity; button releases it
- •Scale: tens of millions affected in the US; high patient satisfaction with implants
